George Demos

698 total citations
11 papers, 356 citations indexed

About

George Demos is a scholar working on Neurology, Psychiatry and Mental health and Physiology. According to data from OpenAlex, George Demos has authored 11 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Neurology, 7 papers in Psychiatry and Mental health and 2 papers in Physiology. Recurrent topics in George Demos's work include Botulinum Toxin and Related Neurological Disorders (5 papers), Parkinson's Disease Mechanisms and Treatments (5 papers) and Schizophrenia research and treatment (5 papers). George Demos is often cited by papers focused on Botulinum Toxin and Related Neurological Disorders (5 papers), Parkinson's Disease Mechanisms and Treatments (5 papers) and Schizophrenia research and treatment (5 papers). George Demos collaborates with scholars based in United States, United Kingdom and Portugal. George Demos's co-authors include Terry Boodhoo, Lynn James, Mitchell F. Brin, Nina Eadie, Janice M. Pogoda, Amanda M. VanDenburgh, Ross Zafonte, Markus Naumann, Susan Abushakra and Frederick C. Beddingfield and has published in prestigious journals such as PLoS ONE, Neurology and Journal of the American Academy of Dermatology.

In The Last Decade

George Demos

11 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
George Demos United States	8	261	116	80	72	51	11	356
Angelika Hanschmann Germany	12	476 1.8×	56 0.5×	114 1.4×	39 0.5×	197 3.9×	35	565
Irina Yushmanova United States	8	121 0.5×	50 0.4×	39 0.5×	69 1.0×	17 0.3×	17	342
Suwanna Setthawatcharawanich Thailand	11	133 0.5×	164 1.4×	61 0.8×	4 0.1×	31 0.6×	34	400
Jason C. Ray Australia	9	52 0.2×	144 1.2×	59 0.7×	5 0.1×	24 0.5×	29	251
Wenxiang Zhong China	12	200 0.8×	36 0.3×	88 1.1×	4 0.1×	30 0.6×	30	349
Fabio Formaglio Italy	10	161 0.6×	20 0.2×	109 1.4×	5 0.1×	31 0.6×	20	303
Ruud CW Vermeulen Netherlands	8	57 0.2×	228 2.0×	21 0.3×	7 0.1×	46 0.9×	11	308
Peggy Chu China	9	73 0.3×	34 0.3×	29 0.4×	12 0.2×	25 0.5×	17	412
Kristin Risa Norway	6	103 0.4×	293 2.5×	22 0.3×	4 0.1×	51 1.0×	10	351
Iqbal F. Hussain United Kingdom	7	110 0.4×	53 0.5×	17 0.2×	6 0.1×	53 1.0×	12	365

Countries citing papers authored by George Demos

Since Specialization

Citations

This map shows the geographic impact of George Demos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Demos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Demos more than expected).

Fields of papers citing papers by George Demos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Demos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Demos. The network helps show where George Demos may publish in the future.

Co-authorship network of co-authors of George Demos

This figure shows the co-authorship network connecting the top 25 collaborators of George Demos. A scholar is included among the top collaborators of George Demos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Demos. George Demos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Forns, Joan, Heather E. Danysh, Lisa J. McQuay, et al.. (2022). Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States. BMC Geriatrics. 22(1). 784–784. 7 indexed citations

Yunusa, Ismaeel, et al.. (2022). Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. Advances in Therapy. 39(5). 1993–2008. 23 indexed citations

Ballard, Clive, Erin P. Foff, Pierre N. Tariot, et al.. (2021). Impact of pimavanserin on cognitive measures in patients with neurodegenerative disease (NDD): results from 4 placebo-controlled clinical studies (2369). Neurology. 96(15_supplement). 1 indexed citations

Layton, J. Bradley, Joan Forns, Mary Ellen Turner, et al.. (2021). Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study. Drugs - Real World Outcomes. 9(1). 9–22. 18 indexed citations

Forns, Joan, J. Bradley Layton, Mary Ellen Turner, et al.. (2021). Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS ONE. 16(1). e0246121–e0246121. 12 indexed citations

Ballard, Clive, Stuart Isaacson, James C. Norton, et al.. (2020). Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. Parkinsonism & Related Disorders. 77. 100–106. 30 indexed citations

Ballard, Clive, Stuart Isaacson, James J. S. Norton, et al.. (2020). Long-term Evaluation of Open-label Pimavanserin Safety and Tolerability in Parkinson’s Disease Psychosis (2096). Neurology. 94(15_supplement). 1 indexed citations

Citrome, Leslie, James C. Norton, Kathy Chi‐Burris, & George Demos. (2017). Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. CNS Spectrums. 23(3). 228–238. 12 indexed citations

Diener, H. C., DW Dodick, Catherine C. Turkel, et al.. (2014). Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. European Journal of Neurology. 21(6). 851–859. 49 indexed citations

10.

Naumann, Markus, Alastair Carruthers, Jean Carruthers, et al.. (2010). Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Movement Disorders. 25(13). 2211–2218. 109 indexed citations

11.

Brin, Mitchell F., Terry Boodhoo, Janice M. Pogoda, et al.. (2009). Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants. Journal of the American Academy of Dermatology. 61(6). 961–970.e11. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact